Whisper it, but we may finally be seeing the IPO window reopening in 2026. | Whisper it, but we may finally be seeing the IPO window reopening in 2026.
The latest firm to top up its venture capital coffers is Austin, Texas-based Santé Ventures, which on Monday announced its ...
2026 could be a big year for this company.
AI-assisted drug discovery isn’t just science fiction anymore, especially as biotechnology and biopharma firms embrace the AI ...
Orna Therapeutics, which engineers immune cells inside the body, will fold into one of the world’s largest drugmakers. The post Eli Lilly snaps up Watertown biotech in $2.4 billion deal appeared first ...
In an era of escalating biological threats, from weaponized pathogens to evolving viruses like Mpox, small U.S. biotechs are stepping up to bolster military readiness and national security.
Four drug companies — Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, and Veradermics — went public this week, ...
The companies Aktis Oncology, Alumis, and Parabilis Medicines bagged the biggest biotech funding rounds overall in January ...
The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.
Eli Lilly will acquire Orna Therapeutics for up to $2.4 billion to gain access to the Watertown biotech's circular RNA ...
Zacks Investment Research on MSN
Here's why IO Biotech, Inc. (IOBT) looks ripe for bottom fishing
Shares of IO Biotech, Inc. (IOBT) have been struggling lately and have lost 31.1% over the past four weeks. However, a hammer ...
Capcom and biotech art group LOM BABY bring Resident Evil’s T-virus to Shibuya PARCO, explaining the exhibit, safety claims, and real biotech context ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results